U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H27FN4O3
Molecular Weight 426.4848
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PALIPERIDONE

SMILES

Cc1c(CCN2CCC(CC2)c3c4ccc(cc4on3)F)c(=O)n5CCCC(c5n1)O

InChI

InChIKey=PMXMIIMHBWHSKN-UHFFFAOYSA-N
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://dx.doi.org/10.4172/2161-1459.1000117

Paliperidone (9-OH-risperidone) is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. Very common adverse effects are: headache, tachycardia, somnolence and insomnia.

CNS Activity

Curator's Comment:: Due to a hydroxyl group in position 9, paliperidone is less lipophilic than risperidone and crosses the blood-brain barrier less easily the parent drug. Experiments in knock-out mice have suggested that the brain entry of both risperidone and paliperidone may be limited by the presence in the blood-brain barrier of the P-glycoprotein, a multidrug efflux transporter, which has a slightly greater affinity for paliperidone than risperidone.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 ng/mL
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.5 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
22.214 ng × h/mL
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
410 ng × h/mL
6 mg 1 times / day steady-state, oral
dose: 6 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
257.3 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
44.9 day
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
22.8 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23 h
single, oral
PALIPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
26%
single, oral
PALIPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Disc. AE: Lethargy, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Lethargy
Tachycardia
Hypokalemia
Dyskinesia
Dystonia
Sources: Page: p.210
252 mg single, oral
Overdose
Dose: 252 mg
Route: oral
Route: single
Dose: 252 mg
Sources: Page: p.47
unhealthy, 16
n = 1
Health Status: unhealthy
Condition: Conduct disorder
Age Group: 16
Sex: M
Population Size: 1
Sources: Page: p.47
Disc. AE: Loss of consciousness...
AEs leading to
discontinuation/dose reduction:
Loss of consciousness
Sources: Page: p.47
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 30
Sex: M
Population Size: 1
Sources:
DLT: Motor tic...
Dose limiting toxicities:
Motor tic
Sources:
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Disc. AE: Depressive symptom, Psychotic disorder...
AEs leading to
discontinuation/dose reduction:
Depressive symptom (0.9%)
Psychotic disorder (0.9%)
Anxiety (0.4%)
Insomnia (0.4%)
Agitation (0.4%)
Abnormal dreams (0.4%)
Libido decreased (0.4%)
Substance abuse (0.4%)
Suicidal ideation (0.4%)
Paranoid schizophrenia (0.4%)
Akathisia (0.9%)
Headache (0.9%)
Dystonia (0.4%)
Dizziness (0.4%)
Tardive dyskinesia (0.4%)
Dyskinesia (0.4%)
Oromandibular dystonia (0.4%)
Extrapyramidal disorder (0.4%)
Erectile dysfunction (0.9%)
Amenorrhea (0.4%)
Ejaculation failure (0.4%)
Galactorrhea (0.4%)
Gynecomastia (0.4%)
Injection site pain (0.9%)
Chest discomfort (0.4%)
Weight increased (0.9%)
Semen volume decreased (0.4%)
Sources: Page: p.565
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Disc. AE: Dyskinesia, Dystonia...
AEs leading to
discontinuation/dose reduction:
Dyskinesia
Dystonia
Tremor
Diaphoresis
Tachycardia
Sources: Page: p.210
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Stroke...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Stroke
Transient ischemic attack (grade 3-5)
Neuroleptic malignant syndrome
QT interval prolonged
Tardive dyskinesia
Hyperglycemia
Dyslipidemia
Weight gain
Hyperprolactinemia
Intestinal stricture NOS
Orthostatic hypotension
Syncope
Leukopenia
Neutropenia
Agranulocytosis
Cognitive impairment
Motor dysfunction NOS
Seizures
Sources: Page: p.1
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Stroke...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Stroke
Transient ischemic attack
Neuroleptic malignant syndrome
QT interval prolonged
Tardive dyskinesia
Hyperglycemia
Dyslipidemia
Weight gain
Hyperprolactinemia
Seizures
Orthostatic hypotension
Syncope
Leukopenia
Neutropenia
Agranulocytosis
Cognitive impairment
Motor dysfunction NOS
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dyskinesia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Dystonia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Hypokalemia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Lethargy Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Tachycardia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Loss of consciousness Disc. AE
252 mg single, oral
Overdose
Dose: 252 mg
Route: oral
Route: single
Dose: 252 mg
Sources: Page: p.47
unhealthy, 16
n = 1
Health Status: unhealthy
Condition: Conduct disorder
Age Group: 16
Sex: M
Population Size: 1
Sources: Page: p.47
Motor tic DLT
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 30
Sex: M
Population Size: 1
Sources:
Abnormal dreams 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Agitation 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Amenorrhea 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Anxiety 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Chest discomfort 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Dizziness 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Dyskinesia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Dystonia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Ejaculation failure 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Extrapyramidal disorder 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Galactorrhea 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Gynecomastia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Insomnia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Libido decreased 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Oromandibular dystonia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Paranoid schizophrenia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Semen volume decreased 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Substance abuse 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Suicidal ideation 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Tardive dyskinesia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Akathisia 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Depressive symptom 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Erectile dysfunction 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Headache 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Injection site pain 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Psychotic disorder 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Weight increased 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Diaphoresis Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Dyskinesia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Dystonia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Tachycardia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Tremor Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Agranulocytosis Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Cognitive impairment Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Dyslipidemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Hyperglycemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Hyperprolactinemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Intestinal stricture NOS Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Leukopenia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Motor dysfunction NOS Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Neuroleptic malignant syndrome Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Neutropenia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Orthostatic hypotension Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
QT interval prolonged Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Seizures Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Stroke Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Syncope Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Tardive dyskinesia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Weight gain Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Transient ischemic attack grade 3-5
Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Agranulocytosis Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Cognitive impairment Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Dyslipidemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Hyperglycemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Hyperprolactinemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Leukopenia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Motor dysfunction NOS Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Neuroleptic malignant syndrome Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Neutropenia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Orthostatic hypotension Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
QT interval prolonged Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Seizures Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Stroke Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Syncope Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Tardive dyskinesia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Transient ischemic attack Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Weight gain Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 61.9 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe detromethorphan
Page: 41, 81
no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe coumarin
Page: 41, 81
no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe chlorzoxazone
Page: 41, 81
no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe lauric acid
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe Caffeine
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe phenytoin
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe phenytoin
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe testosterone
Page: 41, 81
weak [IC50 63.26 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
2001 Jun
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.
2002 Mar
Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.
2002 May
Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.
2002 Nov
Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
2002 Oct
Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
2003 Feb
Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.
2003 Jun
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
2004 May
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
2005 Dec
The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.
2005 Jan
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
2005 Mar
Membrane transporter proteins: a challenge for CNS drug development.
2006
[Paliperidone].
2006 Aug
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
2006 Jul
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.
2006 Jun
Intestinal uptake and biodistribution of novel polymeric micelles after oral administration.
2006 Mar 10
Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography.
2006 May 3
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
2006 Sep
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
2007
Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
2007 Apr
Paliperidone: quo vadis?
2007 Apr
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
2007 Feb
FDA approves new antipsychotic.
2007 Feb 1
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
2007 Jul
Molecule of the month. Paliperidone.
2007 Jun
Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.
2007 Jun 1
Paliperidone (Invega) for schizophrenia.
2007 Mar 12
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
2007 May
Paliperidone extended-release tablets: a new atypical antipsychotic.
2007 May
The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.
2007 Nov
Paliperidone: a new extended-release oral atypical antipsychotic.
2007 Oct
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
2008
New drug update: 2007.
2008 Apr
Gateways to clinical trials. July-August 2008.
2008 Jul-Aug
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
2008 May
Gateways to clinical trials.
2008 Oct
Antipsychotic drugs inhibit the function of breast cancer resistance protein.
2008 Oct
Paliperidone extended-release for the treatment of schizophrenia.
2008 Oct
Choreatic symptoms during and after treatment with paliperidone and escitalopram.
2008 Sep
Secondary delusional parasitosis treated with paliperidone.
2009 Apr
Patents

Patents

Sample Use Guides

In adults is 6 mg administered once daily In adolescents 12-17 years of age is 3 mg administered once daily
Route of Administration: Oral
Paliperidone has dual hyperprolactinemic actions in lactotrophs i) by preserving the coupling of spontaneous electrical activity and prolactin secretion in the presence of dopamine and ii) by inhibiting intrinsic dopamine receptor activity in the absence of dopamine, leading to enhanced calcium signaling and secretion.
Name Type Language
PALIPERIDONE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PALIPERIDONE [USAN]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-
Systematic Name English
3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
PALIPERIDONE [USP MONOGRAPH]
Common Name English
PALIPERIDONE [MART.]
Common Name English
PALIPERIDONE [EMA EPAR]
Common Name English
9-HYDROXYRISPERIDONE
Common Name English
RISPERIDONE SPECIFIED IMPURITY C [EP]
Common Name English
RO76477
Code English
PALIPERIDONE [WHO-DD]
Common Name English
PALIPERIDONE [INN]
Common Name English
PALIPERIDONE [VANDF]
Common Name English
(9RS)-3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDIN-1-YL))ETHYL)-9-HYDROXY-2-METHYL-6,7,8,9-TETRAHYDRO-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Common Name English
NSC-759623
Code English
PALIPERIDONE [ORANGE BOOK]
Common Name English
PALIPERIDONE [USP-RS]
Common Name English
PALIPERIDONE [MI]
Common Name English
RISPERIDONE IMPURITY, 9-HYDROXYRISPERIDONE- [USP]
Common Name English
R-76477
Code English
RO-76477
Code English
PALIPERIDONE [JAN]
Common Name English
INVEGA
Brand Name English
Classification Tree Code System Code
WHO-ATC N05AX13
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
WHO-VATC QN05AX13
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
LIVERTOX 732
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
NDF-RT N0000175430
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
EMA ASSESSMENT REPORTS INVEGA (AUTHORIZED: PSYCHOTIC DISORDERS)
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
EMA ASSESSMENT REPORTS INVEGA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
NCI_THESAURUS C66883
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
Code System Code Type Description
DRUG CENTRAL
4137
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
LACTMED
Paliperidone
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL1621
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
EPA CompTox
144598-75-4
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
WIKIPEDIA
PALIPERIDONE
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
DRUG BANK
DB01267
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
INN
7977
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
USP_CATALOG
1491809
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY USP-RS
CAS
144598-75-4
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
IUPHAR
7258
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
PUBCHEM
115237
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
RXCUI
679314
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C66293
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
FDA UNII
838F01T721
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
EVMPD
SUB23268
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
MERCK INDEX
M8357
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY Merck Index
HSDB
8148
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY